603 related articles for article (PubMed ID: 25584004)
21. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
22. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP
J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811
[TBL] [Abstract][Full Text] [Related]
23. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
[TBL] [Abstract][Full Text] [Related]
25. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
26. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
Douillard JY; Gervais R; Dabouis G; Le Groumellec A; D'Arlhac M; Spaeth D; Coudert B; Caillaud D; Monnier A; Clary C; Maury B; Mornet M; Rivière A; Clouet P; Couteau C
Ann Oncol; 2005 Jan; 16(1):81-9. PubMed ID: 15598943
[TBL] [Abstract][Full Text] [Related]
27. Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer.
Kim JY; Ryoo HM; Bae SH; Kang BW; Chae YS; Yoon S; Baek JH; Kim MK; Lee KH; Lee SA; Song HS; Kim JG
Anticancer Res; 2015 Jun; 35(6):3531-6. PubMed ID: 26026121
[TBL] [Abstract][Full Text] [Related]
28. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer.
Nakamura M; Koizumi T; Hayasaka M; Yasuo M; Tsushima K; Kubo K; Gomi K; Shikama N
Cancer Chemother Pharmacol; 2009 May; 63(6):1091-6. PubMed ID: 18818921
[TBL] [Abstract][Full Text] [Related]
30. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
[TBL] [Abstract][Full Text] [Related]
31. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
Manegold C; Gravenor D; Woytowitz D; Mezger J; Hirsh V; Albert G; Al-Adhami M; Readett D; Krieg AM; Leichman CG
J Clin Oncol; 2008 Aug; 26(24):3979-86. PubMed ID: 18711188
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer.
Tsunoda T; Koizumi T; Hayasaka M; Hirai K; Koyama S; Takabayashi Y; Fujimoto K; Kubo K
Cancer Chemother Pharmacol; 2004 Aug; 54(2):173-7. PubMed ID: 15127230
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
[TBL] [Abstract][Full Text] [Related]
35. Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.
Auliac JB; Chouaid C; Greillier L; Monnet I; Le Caer H; Falchero L; Corre R; Descourt R; Bota S; Berard H; Schott R; Bizieux A; Fournel P; Labrunie A; Marin B; Vergnenegre A;
Lung Cancer; 2014 Sep; 85(3):415-9. PubMed ID: 25082565
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.
Karampeazis A; Vamvakas L; Agelidou A; Kentepozidis N; Chainis K; Chandrinos V; Vardakis N; Pallis AG; Christophyllakis C; Georgoulias V
Clin Lung Cancer; 2011 May; 12(3):155-60. PubMed ID: 21663857
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
Lung Cancer; 2007 Jun; 56(3):363-9. PubMed ID: 17306906
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
39. Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Belani C;
Semin Oncol; 2001 Jun; 28(3 Suppl 9):10-4. PubMed ID: 11441409
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
Qi WX; Shen Z; Yao Y
Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
